ReviewCurrent medical science2026
Beyond Tumor Treating Fields: Multimodal Antitumor Action and the Clinical Potential of Pulsed Electromagnetic Fields.
Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Pulsed electromagnetic fields (PEMFs) are a noninvasive, safe, and well-tolerated physical therapy modality with established applications in musculoskeletal disorders. Their potential role in oncology has attracted increasing interest. This review synthesizes current evidence on the antitumor mechanisms and experimental effects of PEMFs across diverse cancer models. Reported biological effects include the induction of apoptosis, regulation of intracellular calcium homeostasis, inhibition of angiogenesis, modulation of immune responses, induction of oxidative stress, regulation of autophagy and cellular metabolism, and enhancement of sensitivity to radiotherapy and chemotherapy. Preclinical studies suggest that PEMFs can selectively suppress proliferation and promote cell death in malignant cells while exerting comparatively limited cytotoxicity in normal cells. Evidence has been reported in models of breast cancer, glioma, hepatocellular carcinoma, melanoma, and other malignancies. Although clinical investigations remain preliminary, studies conducted over the past two decades support a favorable safety profile and suggest potential therapeutic efficacy, particularly in combination with chemotherapy, radiotherapy, or immunotherapy. Artificial intelligence and machine learning may facilitate parameter optimization and the development of individualized treatment regimens. Ultimately, the integration of PEMFs into routine oncology practice will require well-designed, large-scale randomized controlled trials to standardize treatment protocols, define clinical indications, and establish their role in multimodal cancer care.
Indexed as
Identifiers
42848262What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.